Strategic licensing agreement enables ZoeNCure to build a high-potency, ADC pipeline targeting severe gastrointestinal and liver cancers in India. 

https://www.thehindubusinessline.com/brandhub/pr-release/zoencure-therapeutics-secures-license-for-novel-antibody-platform-from-styx-biotechnologies-to-advance-next-generation-adcs-for-liver-cancer/article71428092.ece